TB 500 UK: Identity, Evidence & UK Peptides
TB 500 UK Explained: A Clear Guide to Identity, Evidence and UK Peptides
TB-500 is a short synthetic peptide related to thymosin beta-4. The two names are frequently used as though they mean the same thing, but they describe different molecular structures. Understanding that distinction makes the research, laboratory documents and regulatory position much easier to follow.
What Is TB-500?
TB-500 is the common name used for a synthetic peptide consisting of seven amino-acid residues.
It corresponds to residues 17 to 23 of a much longer naturally occurring peptide called thymosin beta-4.
Its commonly reported structure is:
Ac-Leu–Lys–Lys–Thr–Glu–Thr–Gln-OH
This is shortened to Ac-LKKTETQ-OH.
The “Ac” at the beginning means that an acetyl group is attached to the first residue. That small detail forms part of the peptide's identity and affects its expected molecular mass.
In plain English: TB-500 is a short laboratory-made fragment taken from the middle of a larger natural peptide. It is related to thymosin beta-4, but it is not the full peptide.
Ac–Leu–Lys–Lys–Thr–Glu–Thr–Gln–OHIs TB-500 a Recognised Generic Medicine Name?
TB-500 is a common or commercial name rather than a widely recognised international non-proprietary medicine name.
That is one reason the name can be used inconsistently. A label reading “TB-500” does not, by itself, confirm the sequence, salt form, purity or exact contents of the vial.
TB-500 and Thymosin Beta-4 Are Not the Same Peptide
They are related, but the difference between them is substantial.
| Feature | TB-500 | Thymosin beta-4 |
|---|---|---|
| General description | Synthetic peptide fragment | Naturally occurring full-length peptide |
| Length | Seven amino-acid residues | Forty-three amino-acid residues |
| Sequence relationship | Corresponds to residues 17–23 | Contains the entire parent sequence |
| Common notation | Ac-LKKTETQ-OH | Full 43-residue sequence |
| Approximate molecular mass | About 889 Da for the reported free peptide | About 4,963 Da |
| Can research be transferred directly? | No. Findings involving the full-length peptide should not automatically be attributed to the seven-residue fragment. | |
A fragment can be related to its parent peptide without behaving as though it were the complete molecule.
Why This Difference Matters
Many online descriptions cite research involving full-length thymosin beta-4 while discussing a vial labelled TB-500.
That can create a misleading impression because the published study may not have examined the seven-residue fragment at all.
Before drawing a conclusion from any paper, readers should check the exact sequence or substance named in the methods section.
Why the Name TB-500 Can Be Confusing
The same short name is sometimes applied to several different material descriptions.
Ac-LKKTETQ
This is the seven-residue, N-terminally acetylated fragment most commonly associated with the TB-500 name.
TB-500 Acetate
This describes material associated with acetate counterions. Counterion content and net peptide content are separate measurements.
Thymosin Beta-4
This is the full 43-residue peptide and should not be treated as another name for the shorter fragment.
Label Without a Sequence
Where a supplier provides only the words TB-500, the precise molecular identity remains uncertain until supporting documents are examined.
A Useful Rule
When a product name is ambiguous, rely on the sequence, terminal groups, material form and analytical results—not the headline name alone.
What Does the Research Evidence Show?
TB-500 has a clearer analytical identity than it has a human clinical evidence base.
Analytical researchers have identified TB-500 products as containing the N-terminally acetylated 17–23 fragment of thymosin beta-4.
Published work includes analytical, metabolic, laboratory and animal studies. These cannot by themselves establish effects or safety in people.
The FDA's 2026 assessment did not identify clinical studies or human exposure data involving TB-500 free peptide or TB-500 acetate.
Without suitable human studies, the frequency and nature of possible adverse effects cannot be established reliably.
What Did the FDA Review Find?
In 2026, the United States FDA published a detailed assessment of TB-500 free peptide and TB-500 acetate.
The review highlighted:
- Inconsistent naming and material descriptions
- Missing or incomplete characterisation information
- No identified human clinical studies
- No established human safety profile
- Unresolved questions involving peptide impurities and aggregation
- Insufficient evidence for the proposed clinical use considered
The FDA document concerns United States compounding policy rather than UK law. It is nevertheless a useful scientific review of the available identity and evidence record.
Does Research on Thymosin Beta-4 Prove Anything About TB-500?
It may help researchers form hypotheses, but it does not establish that the short fragment has the same behaviour as the full peptide.
The exact molecule used in each study must be confirmed before findings are attributed to TB-500.
TB-500 Compared with Related Peptide Names
These materials are sometimes grouped together online, but they have different sequences and scientific identities.
| Material | General identity | Length | Main difference |
|---|---|---|---|
| TB-500 | Acetylated thymosin beta-4 fragment | 7 residues | Commonly written as Ac-LKKTETQ |
| Thymosin beta-4 | Full-length natural peptide | 43 residues | Parent peptide rather than the short fragment |
| BPC-157 | Synthetic pentadecapeptide | 15 residues | Completely different sequence and research history |
| Thymosin alpha-1 | Separate thymosin-family peptide | 28 residues | Not a form of thymosin beta-4 or TB-500 |
| LKKTETQ | Unacetylated sequence notation | 7 residues | Does not state the N-terminal acetyl group |
TB-500 and BPC-157
TB-500 and BPC-157 are separate peptides. Neither is a version of the other.
Where both names appear on one product, the finished mixture would need its own evidence confirming the identity and proportion of each component.
How Do Laboratories Check TB-500?
A reliable laboratory record should connect the claimed sequence with the exact batch tested.
Chromatography separates detectable components and can report the relative area associated with the main peak.
Mass analysis can check whether the observed molecular information is consistent with the expected acetylated fragment.
Suitable fragmentation or peptide-mapping methods can add confidence that the residues appear in the expected order.
Documentation should state whether the sample is described as the free peptide or an acetate-associated form.
Reports should explain whether the stated amount means net peptide, total dried material or a nominal filling target.
The lot number on the analytical report should match the physical material being examined.
What Should Appear on a Useful Certificate?
- The full sequence Ac-LKKTETQ-OH
- The material form
- The expected molecular mass
- The observed identity result
- The chromatographic result and method
- The batch or lot number
- The date of analysis
- The name of the issuing laboratory
- A report number that can be traced or verified
What Does 99% HPLC Purity Mean?
It normally means that the principal peak accounted for approximately 99% of the detected chromatographic peak area under that particular method.
It does not automatically prove:
- That the main peak is TB-500
- That the acetyl group is present
- That the residue order is correct
- That the sample contains the stated net peptide amount
- That every impurity has been detected
- That the material is sterile
- That it is suitable for administration
Purity tells one part of the story. Identity, quantity, material form and batch traceability complete it.
What Is the UK Position on TB-500?
No current UK marketing authorisation for a TB-500 medicinal product was identified in the official sources checked for this guide.
The MHRA decides whether a particular product falls within the legal definition of a medicine.
It considers the complete presentation, including:
- What the substance is
- The claims made directly or indirectly
- Its known pharmacological properties
- Its apparent intended purpose
- Website wording and imagery
- Packaging, reviews and social-media content
A label stating “Research Use Only” may support a genuine laboratory presentation, but it does not override contradictory consumer claims, instructions or promotional material elsewhere.
UK advertising rules also require objective claims to be supported by suitable evidence and restrict medicinal claims for products that do not hold the required authorisation.
Why the Context Matters
A neutral scientific article and a sales page promising physical outcomes are not viewed in the same way. The wording, imagery, links and surrounding commercial content all contribute to the impression made on the reader.
TB-500 and Competitive Sport
The World Anti-Doping Agency's 2026 Prohibited List expressly names thymosin beta-4 and its derivatives, including TB-500.
This prohibition applies independently of whether a product is described as a medicine, supplement or research material.
Athletes and support personnel should rely on official anti-doping resources rather than supplier descriptions or product labels.
Medical and Editorial Review
This final article has been reviewed for medical context, scientific accuracy, evidence presentation, patient-safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide transparent authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a professional background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a professional interest in nutritional sciences, dietology, metabolic health and evidence-based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient-centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board-certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence-based aesthetic care.
Read professional profileFrequently Asked Questions About TB 500 UK
Clear answers to the most common identity, evidence and regulatory questions.
What is TB-500?
TB-500 is the common name used for an N-terminally acetylated seven-residue peptide fragment, usually written as Ac-LKKTETQ-OH.
How many amino acids does TB-500 contain?
The peptide fragment commonly identified as TB-500 contains seven amino-acid residues.
Is TB-500 the same as thymosin beta-4?
No. TB-500 is a short fragment. Full-length thymosin beta-4 contains 43 amino-acid residues.
What does Ac-LKKTETQ mean?
LKKTETQ is the seven-residue sequence. “Ac” indicates an acetyl group attached to the beginning of the peptide.
Is TB-500 acetate the same as TB-500 free peptide?
They share the core peptide, but an acetate-associated form includes counterion material that affects how composition and quantity are reported.
Has TB-500 been studied in humans?
The FDA's 2026 review did not identify human clinical studies or human exposure data involving TB-500 free peptide or TB-500 acetate.
Can thymosin beta-4 studies be used as TB-500 evidence?
Not automatically. The full-length peptide and the seven-residue fragment are different molecular entities.
Is TB-500 authorised as a UK medicine?
No current UK marketing authorisation for a TB-500 medicinal product was identified in the official sources checked for this article.
Does “Research Use Only” decide whether it is legal?
No. UK authorities can consider the substance, claims, intended purpose, website, packaging, imagery and likely use.
Is TB-500 prohibited in sport?
Yes. WADA's 2026 Prohibited List expressly includes thymosin beta-4 and derivatives such as TB-500.
Does HPLC prove that a sample is TB-500?
Not by itself. HPLC supplies chromatographic information, while molecular identity requires suitable supporting analysis.
Does 99% purity mean the vial is 99% net TB-500?
Not necessarily. Chromatographic peak-area purity, net peptide content, counterion content and total material weight are different measurements.
Is TB-500 the same as BPC-157?
No. They are separate peptides with different amino-acid sequences and research records.
The Main Points to Remember
- TB-500 is generally identified as the seven-residue peptide Ac-LKKTETQ-OH.
- It is related to, but different from, full-length thymosin beta-4.
- Research involving the parent peptide should not automatically be attributed to TB-500.
- The name TB-500 can be used inconsistently, so the sequence and material form matter.
- The FDA's 2026 review identified no human clinical studies involving TB-500.
- HPLC purity alone does not establish full molecular identity or net peptide content.
- No current UK marketing authorisation was identified in the official sources checked.
- TB-500 is expressly prohibited under current WADA rules.
Scientific and Official Sources
- Esposito and colleagues: identification of the N-terminally acetylated thymosin beta-4 fragment in TB-500
- Ho and colleagues: analytical detection of N-acetylated LKKTETQ
- United States FDA: 2026 assessment of TB-500 free peptide and TB-500 acetate
- United States FDA: safety concerns involving certain bulk peptide substances
- PubChem: TB-500-related acetylated peptide record
- PubChem: full-length thymosin beta-4
- World Anti-Doping Agency: 2026 Prohibited List
- MHRA: Borderline products and how to tell if a product is a medicine
- Human Medicines Regulations 2012: Regulation 279
- CAP Code Section 12: Medicines and health-related products
